In the study, 52% of people (97 people) were kidney transplant recipients; 19% (35) were liver; 14% (26) were heart; 9% (17) were lung; 3% (six) were kidney and pancreas; and (six) were other multi-organ recipients.
The median age was 48; 69% (129) were female, 87% (163) were white; and 6% (11) were Hispanic or Latino.
Vaccinations occurred at a median of six years following transplant surgery; while all participants were receiving immunosuppression medications to prevent rejection of their transplanted organs.
None of the participants were diagnosed with COVID-19 after vaccination during the course of the study. In addition, the percentage of those that experienced adverse reactions to the vaccine (such as fever or chills) was similar to that seen in large Phase 3 trials.
Organ rejection — a common concern about vaccinating transplant recipients — did not occur in the trial.
The researchers of the study will continue to conduct long-term follow up studies of the participants.
